EMA accepts oral MS treatment Teriflunomide marketing application
Genzyme, a Sanofi company , announced today the European Medicines Agency (EMA) has accepted the filing of the marketing authorization application (MAA) for once-daily oral teriflunomide for the treatment of relapsing forms of multiple sclerosis (MS). Acceptance of the MAA starts the EMA's review process.
"The filing represents another important milestone for teriflunomide and brings us one step closer to offering a new treatment option to patients with relapsing MS," said Bill Sibold, Senior Vice President, Head of Multiple Sclerosis, Genzyme. "As an oral therapy with a promising clinical profile, teriflunomide is extremely well positioned to provide an alternative therapeutic option to patients who are currently taking injectable therapies. Those injectable therapies make up approximately 80 percent of the MS market today."... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/2933
EMA accepts oral MS treatment Teriflunomide marketing app.
EMA accepts oral MS treatment Teriflunomide marketing app.
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 1 Replies
- 1140 Views
-
Last post by Petr75
-
- 0 Replies
- 66 Views
-
Last post by NHE
-
- 5 Replies
- 2488 Views
-
Last post by Jaded
-
- 0 Replies
- 4543 Views
-
Last post by NHE
-
- 0 Replies
- 2226 Views
-
Last post by frodo
-
- 0 Replies
- 2579 Views
-
Last post by Cece
-
- 0 Replies
- 2754 Views
-
Last post by NHE
-
- 2 Replies
- 1334 Views
-
Last post by NHE